Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH

for the Subcommittees on Fibrinolysis, Disseminated Intravascular Coagulation, and Perioperative and Critical Care Thrombosis and Hemostasis

doi:10.1111/jth.14690

Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH

for the Subcommittees on Fibrinolysis, Disseminated Intravascular Coagulation, and Perioperative and Critical Care Thrombosis and Hemostasis

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Original language	English (US)
Pages (from-to)	740-747
Number of pages	8
Journal	Journal of Thrombosis and Haemostasis
Volume	18
Issue number	3
DOIs	https://doi.org/10.1111/jth.14690
State	Published - Mar 1 2020

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/jth.14690

Cite this

for the Subcommittees on Fibrinolysis, Disseminated Intravascular Coagulation, and Perioperative and Critical Care Thrombosis and Hemostasis (2020). Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 18(3), 740-747. https://doi.org/10.1111/jth.14690

Defining trauma-induced coagulopathy with respect to future implications for patient management : Communication from the SSC of the ISTH. / for the Subcommittees on Fibrinolysis, Disseminated Intravascular Coagulation, and Perioperative and Critical Care Thrombosis and Hemostasis.

In: Journal of Thrombosis and Haemostasis, Vol. 18, No. 3, 01.03.2020, p. 740-747.

Research output: Contribution to journal › Article › peer-review

for the Subcommittees on Fibrinolysis, Disseminated Intravascular Coagulation, and Perioperative and Critical Care Thrombosis and Hemostasis 2020, 'Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH', Journal of Thrombosis and Haemostasis, vol. 18, no. 3, pp. 740-747. https://doi.org/10.1111/jth.14690

@article{28d0395d2ed541248cb125653145aa39,

title = "Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH",

author = "{for the Subcommittees on Fibrinolysis, Disseminated Intravascular Coagulation, and Perioperative and Critical Care Thrombosis and Hemostasis} and Moore, {Hunter B.} and Satoshi Gando and Toshiaki Iba and Kim, {Paul Y.} and Yeh, {Calvin H.} and Karim Brohi and Hunt, {Beverley J.} and Levy, {Jerrold H.} and Draxler, {Dominik F.} and Simon Stanworth and Klaus G{\"o}rlinger and Neal, {Matthew D.} and Schreiber, {Martin A.} and Barrett, {Christopher D.} and Medcalf, {Robert L.} and Moore, {Ernest E.} and Mutch, {Nicola J.} and Jecko Thachil and Tetsumei Urano and Scott Thomas and Ecaterina Sc{\u a}rl{\u a}tescu and Mark Walsh",

note = "Funding Information: SG is a consultant for Asahikasei Pharma America and has received honorarium from Asahikasei Pharma Japan. EEM is a co‐founder of ThromboTherapeutics; holds equity in Haemonetics; and has received research funding from Haemonetics, Instrumentation Laboratory, and Stago. MDN holds equity as a board member at Haima Therapeutics; received honoraria from CSL Behring and Janssen Pharmaceuticals; received research funding from Haemonetics, Instrumentation Laboraties, Noveome, and Accriva Diagnostics. HBM is a co‐founder of ThromboTherapuetics and receives research support from Instrument Laboratories. ES has received honoraria from Danube University of Krems, Weill‐Cornell Medicine, University Hospital Zurich Foundation, CSL Behring, and EurAsia Heart Foundation. MAS is a consultant for Haemonetics, Arsenal Medical, and Velico Medical. JHL is on the advisory board for CSL Behring, Instrumentation Laboratories, Janssen, Octapharma, Leading Biosciences, and Merck. MW holds research grants from Haemonetics and has received honoraria from Portola Inc. All other authors have no conflict of interest to report. ",

year = "2020",

month = mar,

day = "1",

doi = "10.1111/jth.14690",

language = "English (US)",

volume = "18",

pages = "740--747",

journal = "Journal of Thrombosis and Haemostasis",

issn = "1538-7933",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Defining trauma-induced coagulopathy with respect to future implications for patient management

T2 - Communication from the SSC of the ISTH

AU - for the Subcommittees on Fibrinolysis, Disseminated Intravascular Coagulation, and Perioperative and Critical Care Thrombosis and Hemostasis

AU - Moore, Hunter B.

AU - Gando, Satoshi

AU - Iba, Toshiaki

AU - Kim, Paul Y.

AU - Yeh, Calvin H.

AU - Brohi, Karim

AU - Hunt, Beverley J.

AU - Levy, Jerrold H.

AU - Draxler, Dominik F.

AU - Stanworth, Simon

AU - Görlinger, Klaus

AU - Neal, Matthew D.

AU - Schreiber, Martin A.

AU - Barrett, Christopher D.

AU - Medcalf, Robert L.

AU - Moore, Ernest E.

AU - Mutch, Nicola J.

AU - Thachil, Jecko

AU - Urano, Tetsumei

AU - Thomas, Scott

AU - Scărlătescu, Ecaterina

AU - Walsh, Mark

N1 - Funding Information: SG is a consultant for Asahikasei Pharma America and has received honorarium from Asahikasei Pharma Japan. EEM is a co‐founder of ThromboTherapeutics; holds equity in Haemonetics; and has received research funding from Haemonetics, Instrumentation Laboratory, and Stago. MDN holds equity as a board member at Haima Therapeutics; received honoraria from CSL Behring and Janssen Pharmaceuticals; received research funding from Haemonetics, Instrumentation Laboraties, Noveome, and Accriva Diagnostics. HBM is a co‐founder of ThromboTherapuetics and receives research support from Instrument Laboratories. ES has received honoraria from Danube University of Krems, Weill‐Cornell Medicine, University Hospital Zurich Foundation, CSL Behring, and EurAsia Heart Foundation. MAS is a consultant for Haemonetics, Arsenal Medical, and Velico Medical. JHL is on the advisory board for CSL Behring, Instrumentation Laboratories, Janssen, Octapharma, Leading Biosciences, and Merck. MW holds research grants from Haemonetics and has received honoraria from Portola Inc. All other authors have no conflict of interest to report.

PY - 2020/3/1

Y1 - 2020/3/1

UR - http://www.scopus.com/inward/record.url?scp=85081076957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081076957&partnerID=8YFLogxK

U2 - 10.1111/jth.14690

DO - 10.1111/jth.14690

M3 - Article

C2 - 32112533

AN - SCOPUS:85081076957

SN - 1538-7933

VL - 18

SP - 740

EP - 747

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

IS - 3

ER -

Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this